Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Lowers Price Target to $152

Benzinga Newsdesk www.benzinga.com Negative 94.9%

Neg 94.9% Neu 0% Pos 0%

Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and lowers the price target from $176 to $152.